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Abstract
As part of an influenza pandemic preparedness program, the WHO analyzes a range of 
potentially pandemic influenza viruses for appropriate vaccines development. Several 
vaccine candidates were prepared using classical genetic reassortment, with the cold-
adapted A/Leningrad/134/17/57(H2N2) (Len/17) master donor strain (MDS) which is 
licensed in the Russia for the live influenza vaccine (LAIV) strains type A production for 
adults and children. The nonpathogenic avian viruses of different subtypes were used 
for reassortant vaccine strains preparation. All vaccine candidates demonstrated a high 
reproductive capacity and cold-adapted (ca-) phenotype in chick embryos. In mice, the 
LAIV of H5N2, H7N3, and H9N2 subtypes provided protection against infection with 
distant influenza viruses. The immunogenicity and protective efficacy of H7N3 LAIV 
was also demonstrated in ferrets. The H5N2 and H7N3 vaccine candidates demonstrated 
the inability to reproduce in chickens, which confirms the safety of their use in areas 
with highly developed agriculture. When tested in clinical trials, vaccine strains of H5N2 
and H7N3 subtypes induce the conversions of antibodies homologous and antigenically 
distant variants. The use of LAIV can be effective against highly pathogenic influenza 
viruses even in the case of incomplete antigenic correspondence between the vaccine 
strain and the infectious virus.
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cross-protection
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Influenza viruses belong to the family Orthomyxoviridae. These are RNA-containing viruses 
possessing a negative fragmented genome. To date, there are four types (serotype) of influ-
enza viruses—influenza A, B, C, and D. Influenza A viruses affect humans and a wide range 
of mammals (horses, pigs, dogs, wild and domestic cats, seals, ferrets) and birds (chickens, 
wild waterfowl, gulls, etc.). Only influenza A viruses are known as causative agents of severe 
epidemics and pandemics. The antigenic properties of influenza A viruses are based on two 
surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA).
Wild waterfowl are considered as a natural reservoir of influenza A viruses which is char-
acterized by high divergence. The 16 HA subtypes and nine NA subtypes were detected in 
migratory waterfowl and poultry [1]. Sometimes, avian influenza viruses overcome the inter-
species barrier and infect poultry and mammals. Avian influenza viruses of subtypes H5N1, 
H7N3, H7N7, H7N9, and H9N2 may become pathogenic for humans and occasionally cause 
very severe infections. As part of an influenza pandemic preparedness program, the World 
Health Organization (WHO) analyzes a range of zoonotic and potentially pandemic influenza 
viruses for the development of appropriate vaccines as seasonal influenza vaccination does 
not protect against pandemic avian influenza viruses [2].
After isolation of the first influenza viruses in 1933–1936, the development of influenza 
vaccines in England, the United States, Australia, and in the USSR began. The devel-
opment of active immunization against influenza using live attenuated vaccines was 
conducted in Russia under the leadership of A.A. Smorodintsev since 1937, and in the 
USA since 1960, where the group of H.F. Maassab also obtained cold-adapted attenu-
ated variants of influenza viruses A and B. At present, two types of LAIVs are com-
mercially available. The first, based on cold-adapted master donor viruses (MDVs) A/
Leningrad/134/17/57 (H2N2) and B/USSR/60/69 [3–5], was licensed in 1987 for the people 
3 years and older as Ultravac (Microgen, Russia). The second, known as FluMist based 
on cold-adapted MDVs, A/Ann Arbor/6/60ca (H2N2), and B/Ann Arbor/1/66ca, was 
licensed in 2003 (MedImmune, Inc., USA). FluMist is used for the prevention of influenza 
in persons younger than 49 and older than 2 years of age [6]. According to World Health 
Organization (WHO), vaccination prevents influenza in 80–90% of vaccinated people, 
and the economic effect of influenza vaccinations is 10–20 times higher than the cost 
of vaccination. In the past 10 years, attention was paid due to the advantages of LAIV 
that cause the formation of systemic and strong local (secretory) immunity. By contrast, 
parenteral inactivated influenza vaccines (IIV) stimulate mainly the formation of serum 
strain-specific antibodies which offer only limited protection against newly emerging 
viruses [7]. Intranasal implementation of LAIV produces immune response similar to 
natural infection and therefore induces an earlier, broader, and more long-lasting pro-
tection than inactivated vaccines [8]. Besides, the cost of live vaccine is five times less 
than inactivated vaccine, and the productivity of the biotechnological production pro-
cess is significantly higher which is also important in the event of pandemic.
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2. Avian influenza in humans
Most avian viruses are initially low virulent for birds, causing only transient asymptomatic 
intestinal infections in wild waterfowl [9]. Viruses of subtypes H5 and H7 can be widespread 
among poultry, while acquiring the increased pathogenicity. This was observed during out-
breaks caused by H5N2 viruses in 1983 or 1994–1995 in North America [10, 11], subtype H7 
(H7N7 or H7N2)—in Europe and in Australia [12]. For the first time, “bird plague,” a dis-
ease caused (as is now known) by highly pathogenic influenza viruses, was described in 1878 
during an outbreak among chickens in Italy. The outbreak causative agent was isolated in 
1902 (virus A/Chicken/Brescia/1902 (H7N7)). During similar outbreaks, repeatedly observed 
in Europe and around the world, several other viruses of H7 subtype were isolated. In 1955, 
those viruses were identified as belonging to a group of influenza viruses [13]. The first of 
the highly pathogenic (HP) viruses of the H5N3 subtype—the A/Tern/South Africa/61—was 
isolated in 1961 [14]. HP avian influenza viruses can cause a mass death of chickens in a short 
time as a result of dissemination of infection in poultry with rapidly progressive neurologic 
symptoms, diarrhea, and fatal outcome. Until 1997, there was no obvious evidence of direct 
infection of humans with avian viruses. Nevertheless, serological studies revealed the pres-
ence of antibodies against avian viruses of various subtypes in human sera in southern China, 
Hong Kong, and East Asia, indicating exposure of some people to avian influenza viruses [15].
2.1. H5N1 influenza viruses
For the first time, attention to H5 avian influenza viruses as possible pandemic agents was 
brought in May 1997 in Hong Kong during a mass outbreak among chickens when the avian 
virus H5N1 was isolated from a child who died from viral pneumonia [16]. To the end of 
1997, an infection with the virus H5N1 similar to poultry viruses identified in the region was 
confirmed in another 17 people, five of whom died [17].
It is possible that before the appearance of the virus H5N1 in humans, a series of reassort-
ments during the circulation of a number of precursor viruses in birds have occurred. Thus, 
HA of H5N1 viruses isolated from humans were almost identical to those of the A/Goose/
Guandong/1/96 (H5N1) [18], and NA may have been acquired from the virus H6N1 [24]. It is 
assumed that the internal genes were borrowed from the same H6N1 virus or H9N2 A/Qail/
Hong Kong/G1/97 (H9N2) influenza viruses during transmission from waterfowl to quails 
and chickens [19].
The mechanisms of avian influenza viruses “step-by-step” adaptation to new hosts are well 
characterized [20]. The change in host cell specificity and the increase in the pathogenicity of 
influenza viruses can be influenced either by amino acid substitutions in the receptor bind-
ing site of HA or by substitutions affecting the conformation and steric availability of this 
center. In particular, this can be influenced by changes in the number of glycosylation sites or 
their localization. High pathogenicity of avian influenza viruses in mammals is polygenic in 
nature. The HA of H5 or H7 HP viruses with a polybasic cleavage site is known as a primary 
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virulence factor, although the unusual severity of clinical manifestations during human infec-
tion with influenza H5N1 viruses can also be associated with mutations in internal proteins 
(PB1-F2, PB2) and non-structural (NS) proteins.
From 1997 to 2001, the HA of H5N1 viruses remained antigenically conserved, although, 
since 2003, there has been an unusually high level of H5N1 viruses evolution. The HP H5N1 
viruses isolated from poultry and humans separated into three branches that differ antigeni-
cally and genetically [21]. During the outbreak in 2005 on Lake Qinghai, a number of HP 
H5N1 viruses were isolated from wild waterfowl [22]. This may indicate a reverse drift of 
similar viruses from poultry to wild birds, which was not observed previously. Along with 
H5 HA evolution, the extensive reassortment of avian influenza viruses in birds in China 
resulted in new H5 viruses possessing different NA subtypes (H5N2, H5N5, H5N6, and 
H5N8) and internal protein genes. In 2014, HA gene segments of H5N1, H5N2, H5N5, H5N6, 
and H5N8 were designated as clade 2.3.4.4., which were detected in birds in 40 countries in 
Africa, Asia, and Europe [23].
WHO has consistently recorded cases of human infection caused by HP influenza H5N1 
virus, many of which had fatal outcomes. The clinical features of human infection caused 
highly pathogenic H5N1 viruses are characterized not only by primary viral pneumonia but 
also by complications with acute distress syndrome and poly-organ lesions [24].
At present, cases of human infection with the avian influenza H5N1 virus were decreased 
compared to the early 2000s. From 2003 to 2009, 468 cases of this disease were registered in 
16 countries, mainly in Vietnam, China, Indonesia, Thailand, and Egypt. In 2010–2014, the 
number of cases was two times decreased (233 people). In 2016, the virus continued to infect 
people in only one country—Egypt (10 cases, three of them with a fatal outcome). In 2017, 
again in Egypt three cases were recorded, one of which was fatal. Thus, even when the abso-
lute number of cases was decreased, mortality remains extremely high. In total, according 
to WHO data, by mid-2017, 859 people were infected with influenza H5N1, 453 (53%) from 
which died [25].
During the outbreak in Hong Kong in 1997, there was no direct evidence of a sustained 
human-to-human transmission of H5N1 viruses, although antibodies against H5 viruses were 
detected in 3.7% of physicians who had contact with H5-infected patients [26]. In 2008, trans-
mission of an infection with avian influenza H5N1 from a son to his father was registered in 
China [27]. Under conditions of the continuous appearance HP H5N1 viruses in the humans, 
there is a risk of such a transmission during close contacts.
2.2. H7N9 influenza viruses
On March 31, 2013, the first three cases of human infection with the avian influenza H7N9 
virus were registered in China. In all three cases, an infection of the respiratory tract was 
complicated with severe pneumonia. Two patients died, the third was in a critical condition 
for a long time, but recovered. Since then, the number of laboratory-confirmed cases in China 
has increased every day. In addition to severe and lethal cases, the sero-diagnostics methods 
have proved the asymptomatic course of the disease in workers of poultry farms. From March 
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2013, there were 1566 cases of avian influenza H7N9 in the world, of which 613 (39%) were 
fatal [28]. At the same time, 88% of the infected developed severe pneumonia, 68% was hospi-
talized in the intensive care unit. Mortality in different years ranged from 31 to 39%.
Experts believe that the virus H7N9 is not likely transmitted from person to person, but 
can spread with prolonged contact, especially when people care for sick family members. 
Moreover, the reassortment of several viruses is also not excluded. Genome analysis of 
human-isolated H7N9 viruses has shown adaptive evolution and convergent changes in 
eight viral genes, including sites in the PB2 gene (Q591K, E627K, and D701N), in HA (R156K, 
V202A, and L244Q), and in NA (R289K). These substitutions are known as playing a role in 
crossing species barriers from avian to human [29].
2.3. H9N2 influenza viruses
The H9N2 influenza viruses readily transmit from birds to animals and humans due to 
the easy appearance of variants that have an affinity for sialic receptors in mammals [30]. 
Sero-epidemiological studies revealed antibodies to viruses H9N2 among 15% of poultry 
workers in China [31]. Viruses H9N2 were isolated from people with symptoms of respi-
ratory infection in Hong Kong and China from 1997 to 2009 [32] belonging mainly to the 
antigenic G1 line, unlike other H9N2 viruses isolated from swine and poultry belonging 
to the antigenic variety G9 [33]. Phylogenetic analysis showed that after 1994, Eurasian 
H9N2 after complex genetic reassortment of G1 and G9 viruses circulating among wild 
and domestic birds formed several antigenic lines [34]. The H9N2 viruses, which caused 
human cases, were not HP as they did not possess highly cleavable HA and were not 
highly virulent for poultry, although molecular analysis demonstrated similarity of genes 
for internal proteins with HP H5N1 viruses, which caused an outbreak among people in 
1997 [35]. Due to the fact that the avian influenza viruses of the H9 subtype are transmit-
ted to humans, have genetic similarity to the H5N1 viruses, and are widespread in Asia, 
Europe, and the Middle East, the WHO has included H9N2 vaccine development in the 
overall plan for pre-pandemic training [36].
2.4. H6N1 influenza viruses
Serological studies in Southern China revealed that 13% of people from different provinces 
have antibodies to the influenza virus of H6 subtype [37]. Phylogenic analysis of influenza A 
viruses indicates that the closely related genes coding the internal proteins could be found in 
influenza A viruses of different subtypes and that the reassortment between the avian and 
human influenza viruses is possible [38]. It was also shown that some of the fragments of 
the NP and NA genes of highly pathogenic H5N1 viruses originated from the H6 virus of 
wild ducks [18, 39]. Therefore, the avian influenza viruses of H6N1 subtype may represent a 
potential danger for humans.
Thus, various avian influenza viruses can pose a threat to humans that necessitates the 
development of a corresponding vaccine strain for the protection of humans from possible 
infection. As part of an influenza pandemic preparedness program, the WHO monitors the 
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number of zoonotic and potentially pandemic influenza viruses to schedule candidates for 
the development of appropriate vaccines [40].
3. Development of live influenza vaccines against potentially 
pandemic avian influenza
The LAIVs preparation against potentially pandemic avian influenza viruses is conducted in 
two directions: the preparation of vaccine strains using classical genetic reassortment in chick 
embryos or through reverse genetics (RG) technique. The first attenuated A/Ann Arbor/6/60 
(H2N2)-based vaccine strains were obtained by reverse genetics shortly after H5 influenza 
outbreaks in Hong Kong in 1997 [41].
The vaccine candidates containing internal genes from the attenuation donor, and the sur-
face antigens from viruses A/Hong Kong/156/97 (H5N1) or A/Hong Kong/483/97 (H5N1) with 
RG-modified HA demonstrated an attenuated phenotype for ferrets and chickens. Both reas-
sortants caused seroconversions in chickens, which confirm the sensitivity of chickens to these 
vaccine strains despite the att-phenotype [42]. By RG methods, three reassortant strains based 
on the A/Ann Arbor/6/60 (H2N2) were prepared in the Vero cell line [43]. As a source of surface 
antigens, viruses H5N1 of 1997, 2003, and 2004 years of isolation with RG-modified HA were 
used. It was shown that a double immunization with LAIV from a strain isolated in 1997 com-
pletely protected mice from infection with later “wild” isolates, including the isolate obtained 
in 2005—A/Indonesia/05/2005 (H5N1). The use of HP viruses requires increased biosecurity 
level laboratories, certified cell lines, and RG techniques. The HP avian viruses found in nature 
cannot be used directly to prepare influenza vaccines because they would not grow in eggs 
and might be dangerous to people. The RG-modified viruses do not cause severe illness in 
birds and that also will grow well in chicken eggs (so that vaccine manufacturers can use it 
to produce vaccine). An alternative approach is to use low pathogenic surrogate viruses that 
show antigenic similarity to HP viruses. In this regard, the identification of non-pathogenic 
variants, which are antigenically close to potentially pandemic strains, may be very important.
Another vaccine candidate based on A/Ann Arbor/6/60, containing HA and NA from virus A/
duck/Hokkaido/69/2000 (H5N3), A/chicken/Hong Kong/G9/97 (H9N2), or A/Chicken/British 
Columbia/CN-6/04 (H7N3) was prepared by classical genetic reassortment methods in the 
chick embryos (CE) [44–46]. The vaccine strains exhibited ts-, ca-, and att-phenotype and pro-
vided protection against infection with the wild-type virus in mice and ferrets.
3.1. Development of reassortant vaccine strains based on a/Leningrad/134/17/57 
(H2N2) MDV
To prepare vaccines based on A/Leningrad/134/17/57 (H2N2) MDV, several non-pathogenic 
avian viruses of different subtypes (A/duck/Potsdam/1402–6/1986 (H5N2), A/mallard /The 
Netherlands/12/2000 (H7N3), A/Hong Kong/1073/99 (H9N2), A/quail/Hong Kong/G1/1997 
(H9N2), and А/herring gull/Sarma/51 s/2006 (H6N1)) were used. The HP avian influenza 
viruses of subtypes H5 and H7 contain a HA insertion from several positively charged amino 
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acid residues (lysine and arginine) in the proteolytic cleavage site [47], which causes effective 
cleavage of HA by intracellular proteases expressed in most organs and tissues of birds and 
mammals. Unlike HP avian influenza viruses, non-pathogenic viruses contain a single arginine 
residue (R) in the cleavage site [44]. For non-pathogenic viruses proteolytic activation, the pres-
ence of trypsin-like enzymes is required, which is expressed by a limited range of cells and is 
found in the airways.
The reassortant vaccine strains were prepared in the Virology Department, Institute of Experi-
mental Medicine, using classical genetic reassortment in CE as previously described [48]. The 
H5N2 reassortant virus inherited only the HA gene from the H5N2 parent virus, and the 
remaining seven genes from the Len/17 MDV (7,1 genome composition) [49]. The reassortants 
of subtypes H7N3, H9N2, and H6N1 inherited the HA and NA from parental avian influenza 
viruses (6,2 genome composition). All the reassortant strains were studied for temperature-
sensitive (ts-) and cold-adapted (ca-) phenotype [49–52]. For those purposes, the reassortant 
viruses were propagated in CE for 2 days at 25, 34, and 40°C. The yield of “wild-type” avian 
influenza viruses at 40°C was the same or greater than at 34°C. Only when the temperature 
was increased to 41°C, the reproduction of these strains was partially limited. Thus, the high 
degree of temperature resistance of all the above viruses was demonstrated. In contrast to 
parental avian viruses, all vaccine candidates poorly reproduced at 40°C in titers not exceeded 
1.5–1.8 log10 EID50/ml. At the same time, these reassortant strains grew well at low tempera-
tures. Thus, all obtained reassortants acquired the genes of internal and nonstructural pro-
teins from the A/Leningrad/134/17/57 (H2N2) MDV inherited the ts- and ca-phenotype. The 
pronounced difference in optimal reproductive conditions between the temperature-resistant 
viruses of avian influenza and the cold-adapted attenuation donor is due to the properties of 
viral polymerases [53]. This difference in the temperature optimum of the parental viruses 
may facilitate the isolation of the reassortant viruses possessing the desired gene composition 
after selective passages at a lower temperature.
3.2. Immunogenicity and cross-protection in mice
The ability of LAIV to induce antibodies not only to the homologous variant subtype but 
also to cross-reacting antibodies to antigenically different variants including HP variants was 
shown in several mouse studies [50–52, 54–56].
Among all vaccine candidates based on non-pathogenic avian influenza viruses, the H6N1 
LAIV was characterized by the highest HI titers in mice after a single administration 
(GMT = 17.4). The LAIV of H7N3 subtype raised serum antibodies not only against the 
homologous virus but also against H7N9, which possessed the difference of 3% in the HA 
amino acid sequence. In the sera from mice double-vaccinated with H7N3 LAIV, serum HI 
titers against H7N9 were 20–40 times higher than against H7N3 (P < 0.05) [56]. At the same 
time, local IgA levels were higher against homologous H7N3 compared with H7N9 after vac-
cination with LAIV. The H5N2 LAIV induced detectable HI and neutralizing antibody titers 
only against the homologous H5N2 virus, perhaps due to the genetic differences between 
H5N2 vaccine strain and infectious viruses H5N1 isolated in 1997, 2003, and 2005 (10–12% 
differences of the HA1 amino acid sequence).
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Nevertheless, immunization using virus H5N2 of 1986 resulted in a significant level of protec-
tion in experimental infection of mice (Figure 1).
Data on the protective efficacy of reassortant vaccine strains against intranasal challenge with 
avian influenza viruses are summarized in Table 1. When the mice were challenged with 
HP H5N1 viruses following immunization with H5N2 LAIV, the infectious viruses were not 
isolated from nasal passages or from the brain [54, 55]. Limited reproduction of HP viruses in 
the respiratory tract of mice and preventing a systemic infection, including neuro-infections, 
are important advantages of LAIV, especially in respect with data on the neurogenic pathway 
of generalization of infection caused by HP H5N1 viruses [58]. The absence of nasal infec-
tion correlated with high titers of secretory virus-specific IgA viruses in nasal swabs. The 
local immune response of the mucous membranes of the body serves as the first and most 
significant barrier for many viral infections, including influenza [59]. Due to their polymeric 
structure, IgAs have several times higher anti-hemagglutinating and neutralizing activity 
compared to IgG [60] and are also more stable and more cross-reactive. In addition, IgA can 
interact with the surface proteins of the influenza virus intracellularly, during trans-cyto-
sis [61]. With respect to LAIV, it is still unclear how antibody-mediated immune response 
is related to protective efficacy. Mechanisms of cross-immunity in influenza are mediated 
by several factors, among which the cellular immune response is very important. Cellular 
immunity is involved in virus clearance and in activating the humoral immune response. 
In this regard, the production of Th1 and Th2 marker cytokines in vitro by splenocytes from 
mice immunized with H5N2 LAIV and whole-virion H5N2 IIV was compared [55].
Both LAIV and IIV caused the cytokines production by splenocytes of immunized mice in 
response to stimulation with both whole H5N1 virus and recombinant H5 HA. While immuni-
zation with LAIV caused higher levels of IFN-γ production by splenocytes of mice stimulated 
with H5N1 viruses, immunization with IIV induced IL-4 and IL-10 production. Interestingly, 
Figure 1. Influenza virus-specific serum antibodies and local IgA in mice after intranasal (i.n.) immunization with LAIV 
[50–52, 54–56]. *Nd, not done.
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after immunization with the H2N2 MDV, the IFN-γ production by splenocyte of mice occurred 
only in response to stimulation with whole virus H5N1, but not purified HA. This may indi-
cate the directivity of hetero-subtypic immunity to conserved epitopes of viral proteins [55].
3.3. Pathogenicity for chickens
Several experiments with vaccine candidates H5N2 and H7N3 were performed at Southeast 
Poultry Research Laboratory, GA, USA. Those studies demonstrated that the ca- reassortants 
of avian viruses adapted to a lower temperature of reproduction were unable to either infect 
a bird or be released into the environment. This was confirmed by the absence of virus isola-
tion from the gastrointestinal tract of birds, as well as the impossibility in the determination of 
specific antibodies (Table 2).
A high degree of attenuation of H5N2 and H7N3 reassortants in chickens (up to a total inability) 
to reproduce confirms the safety for poultry farms during the production and use of such strains.
3.4. Study in primates
If the genetically homogeneous population using linear mice is the most appropriate model for 
assessing the molecular mechanisms of pathogenicity, the use of genetically heterogeneous 
Challenge virus Dosage Vaccine 
groups
Protection Refs.
Virus titers (log10EID50/
ml)
Lethality
Lung Noses Brain
A/Hong Kong/483/97 (H5N1) 50 LD50 H5N2 
LAIV
1.9 ≤0.8 ≤0.8 0% [54]
PBS 5.9 4.0 4.3 100%
A/Hong Kong/213/2003 (H5N1) 100 MID50 H5N2 
LAIV
1.8 Nd* Nd Na** [54]
PBS 5.3 Nd Nd Na
A/Vietnam/1203/2004 (H5N1) 200 LD50 H5N2 
LAIV
1.6 0.8 0.8 0% [55]
PBS 6.1 4.7 4.5 100%
A/chicken/Kurgan/02/2005 (H5N1) 27 LD50 H5N2 
LAIV
Nd Nd Nd 13% [57]
PBS Nd Nd Nd 100%
A/mallard/The Netherlands/12/2000 
(H7N3)
7 lg EID50 H7N3 
LAIV
≤1.5 ≤1.5 ≤1.5 Na [50]
PBS 5.7 4.2 ≤1.5 Na [50]
A/chicken/Hong Kong/G9/97 (H9N2) 7 lg EID50 H9N2 
LAIV
3.4 1.1 Nd Nd [51]
PBS 6.9 2.0 Nd Nd [51]
*Nd, not done.
**Na, not applicable.
The virus was not lethal for mice.
Table 1. Protection against infection with avian influenza viruses.
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animals (ferrets, primates) better allows one to assess the effect of natural host defense 
factors in mammalian infection by avian influenza viruses. The use of primates is one of 
the most promising areas in the study of human infectious pathology. The evolutionary 
relationship and biological similarity between humans and monkeys make them unique 
objects in the modeling of infectious diseases. However, the lower primates, while remain-
ing closest to humans than other mammals, differ significantly in physiological characteris-
tics from them. In experiments on the hybridization of nuclear DNA, it has been established 
that the similarity of man to chimpanzee reaches 90–98%, with lower monkeys—50–75% 
whereas in rodents, this index is not more than 20% (unpublished data).
The use of lower primates as models makes it possible to establish the duration and sequence 
of biochemical, metabolic, and physiological responses in the course of the development of 
the disease, which are then used to evaluate various preventive and therapeutic measures 
[62]. The use of primates for the modeling of the pathogenesis of influenza H5N1 in people of 
preclinical evaluation of vaccine preparations by a group of scientists from The Netherlands 
is described [63].
Before the clinical trials, the safety, immunogenicity, and protective properties of the LAIV 
based on strain A/17/duck/Potsdam/86/92 (H5N2) were studied by intranasal immunization of 
Java macaques [64]. None of the four monkeys immunized with H5N2 LAIV at a dose of 6.9 log10 
EID50/ml showed no adverse reactions with either temperature or behavioral changes or weight 
loss. The vaccine virus multiplied in the upper respiratory tract and was isolated in two of four 
monkeys, on days 3–5 after the first vaccination with the maximum titer of 4.2 lg EID50/ml. The 
absence of viremia and a temperature reaction in the same period indicates the local immuniza-
tion process. In three of four monkeys, double immunization caused neutralizing antibodies to 
H5 viruses in titers 1:40–1:160. Twenty-one days after the end of the immunization cycle, the 
Virus I.v. pathogenicity test* I.n. pathogenicity and infectivity data** Refs.
Virus isolation on day 3 p.i. Seroconversions 
(AGID).
Morbidity Mortality
Morbidity Mortality Oropharyngeal 
swabs
Cloacal 
swabs
Len/17 0/8 0/8 0/5 0/5 0/5 0/5 0/5 [53]
Len17/H5N2 0/8 0/8 0/5 0/5 0/5 0/5 0/5
H5N2-wt 0/8 0/8 0/5 0/5 3/5 0/5 0/5
Len17/Н7N3 0/8 0/8 0/5 0/5 0/5 0/5 0/5 [49]
H7N3-wt 5/8 5/8 2/5(101.1)*** 1/5(100.91)*** 5/5 0/5 0/5
*Groups of eight 5-week-old specific pathogen-free (SPF) chickens were infected intravenously (i.v.) with and observed 
daily for 10 days for clinical signs and death.
**Groups of five chickens were infected intranasally (i.n.) with 6 log10 EID50/0.1 ml. The oropharyngeal and cloacal swabs 
were collected 3 days post infection (p.i.) and titrated in eggs for assessing viral replication. The chickens were observed 
for clinical signs of disease and death for 14 days. To determine infectivity, sera were collected 21 days p.i. and tested for 
the presence of antibodies by agar gel immunodiffusion (AGID) test.
***Mean virus titers (EID50/0.1 ml).
Table 2. Pathogenicity and infectivity data for chickens.
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animals were infected in a combined method using intratracheal and intranasal administration 
of 7.5 lg EID50/ml primate-adapted influenza virus A/Chicken/Kurgan/2/05 (H5N1). According 
to the summary data on clinical reactions and virus isolation from the respiratory tract, the vac-
cine protected at least 50% of immunized animals against the H5N1 infection.
3.5. Study of the H5N2 and H7N3 reassortants in phase I clinical trials
The randomized, double-blinded, placebo-controlled phase I trials were conducted in healthy 
adults at the St. Petersburg Institute of Influenza [65, 66]. Both H5N2 and H7N3 LAIV were 
safe for volunteers. In the genome of the isolated vaccine virus, all the mutations known 
for the MDV were conserved [65, 66]. Data on the LAIV when used in humans confirm the 
concept of attenuation of influenza viruses by reassortment with MDV and association of the 
ca- phenotype with an attenuation for people. For the vaccine virus isolation from the nasal 
washes, two to three passages were required on MDCK cell culture, indicating a very low 
content of the virus. These data confirmed LAIV implementation safety for contact persons.
The post-vaccination antibody response was assessed using the HI test, which is still posing 
as the “gold standard” for the evaluation of influenza vaccine immunogenicity, the micro-
neutralization (MN) test which is supposed to be more sensitive compared to the HI in the 
detection of serum antibodies after immunization against potential pandemic subtypes. Local 
IgA response in nasal washes was estimated using ELISA (Figure 2).
According to the results of three tests, more than 80% of the vaccinated subjects responded 
to immunization with a significant increase in serum or local antibodies [65, 66]. Moreover, 
after double vaccination with H5N2 LAIV, 30.8% of vaccinated volunteers responded to the 
HA antigen of the A/Indonesia/05/2005xPR8 IBCDC-RG (H5N1). When serum samples of 
volunteers vaccinated with H7N3 LAIV were tested for the anti-H7N9 HI antibodies, the 
Figure 2. Immunogenicity of H5N2 and H7N3 LAIV in volunteers after boost immunization [65–67].
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seroconversions were found among 44.8% of vaccinated persons [67]. These data indicate the 
substantial level of cross-reactive antibodies induced by LAIV against distant avian influ-
enza viruses. The two doses of LAIV raised both CD4 and CD8 T-memory-cell responses in 
peripheral blood of healthy volunteers on day 21 after boost immunization [67].
Previously, when studying the immunogenicity of inactivated vaccines based on potentially 
pandemic avian influenza viruses, both the experiment and the clinical trials showed a low 
immunogenicity of such preparations, according to generally accepted criteria for serocon-
version of HI antibodies. The European Committee for the Control of Medicines has estab-
lished the following criteria for the immunogenicity of vaccine preparations based on both 
epidemic and potentially pandemic influenza viruses: the multiplicity of antibody growths 
of at least 2.5 for individuals 18–60 years old and the development of reliable seroconversion 
in 40% of the vaccinated [68]. Obviously, the detection of only strain-specific HI antibod-
ies is not sufficient to fully characterize the immunogenicity of the LAIV [69]. Moreover, it 
remains unclear what antibody titer can be considered protective against potentially pan-
demic viruses—1:20 or 1:40. Recently, it was shown that neuraminidase-inhibiting (NI) anti-
body titers better correlate with protection and can be an independent predictor of reduction 
of influenza disease severity [70]. Therefore, neuraminidase immunity should be considered 
when studying susceptibility after vaccination as a critical target in future influenza vaccine 
platforms. In this connection, the NI antibodies in the sera of volunteers after H5N2 immuni-
zation were estimated (Table 3). The two doses of the monovalent LAIV H5N2 raised a sta-
tistically significant increase in the NI antibodies against vaccine strain. More than twofold 
increase in antibodies was obtained among 19.5–33.3% of those vaccinated. The MN test and 
NI assay titers in the same sera of the vaccinated volunteers were 73.2% corresponded and 
suggested a statistically significant correlation between the values in antibody titers revealed 
in both tests (p = 0.04).
4. Conclusions
• The use of non-pathogenic avian viruses as a source of surface antigens combined with 
the use of cold-adapted “donors” of attenuation can be a significant advantage in the de-
velopment of vaccine strains for LAIV against potentially pandemic influenza using clas-
sical genetic reassortment in CE. Low pathogenic avian influenza viruses do not contain a 
Vaccine Groups NI data Ref.
Number of 
≥2-fold antibody 
rises
Geometric mean titers (GMT) GMT 
fold-rise
Before 
vaccination
After revaccination
LAIV H5N2 (6.9 log10 
EID50/0.5 ml)
LAIV 6 (33.3) 5.0 9.9 2.0* [71]
Placebo 0 (0) 9.9 7.5 0
*P < 0.05.
Table 3. Serum NA-inhibiting antibodies against H5N2 LAIV 21 days after second vaccination.
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polybasic amino acid insertion in the cleavage site and therefore do not require modifica-
tion by reverse genetics methods prior to reassortment.
• A high degree of attenuation of the reassortants of subtypes H5N2 and H7N3 in chick-
ens, up to a total inability to reproduce, confirms the safety for poultry farms during the 
production and use of such strains. The high yield of the obtained reassortants in the CE 
makes it possible to produce a large amount of viral material, which allows their use for the 
production of both LAIV and IIV.
• In preclinical and clinical studies, LAIV based on non-pathogenic avian influenza vi-
ruses causes the formation of systemic and secretory antibodies including those against 
antigenically distant viruses. In animal models, LAIV based on non-pathogenic avian 
influenza viruses provided protection against HP variants that appeared much later. Pro-
tection from lethal infection with HP viruses was observed even in the absence of HI an-
tibodies. This suggests that the use of LAIV may be effective against HP influenza viruses 
even in the case of incomplete antigenic correspondence between the vaccine strain and 
the infectious virus.
• In general, studies in mice represent an adequate preclinical model for studying the prop-
erties of reassortants of non-pathogenic avian influenza viruses, since data on the safety, 
immunogenicity, and cross-reactivity of post-vaccinal antibodies obtained in mice were 
confirmed in clinical trials.
• In the clinical trials of LAIV of potentially pandemic subtypes, the detection of only strain-
specific HI antibodies is not sufficient to fully characterize the positive effect of immuniza-
tion on the stimulation of antiviral immunity, which in this case is mediated by a variety of 
other factors, both humoral and cellular.
5. Future perspectives
In the face of a pandemic threat, only live vaccines can eliminate the risk of losses from 
increased morbidity and mortality, as it was demonstrated in the cases with smallpox 
eradication and polio control. The conducted studies clearly showed that the classical 
genetic reassortment method allows obtaining high-yield, harmless and immunogenic 
LAIVs on the basis of an attenuated donor virus. In the post-pandemic period, when the 
direct threat of infection recedes, the main task is the search for optimal regimens for the 
use of new pandemic vaccines, including (1) the possibility of including such vaccine 
strains in the composition of polyvalent live vaccines; (2) prime-boost schemes using both 
LAIV and IIV; (3) the development of recommendations for vaccination of people with 
an increased risk of influenza infection complications; (4) a comprehensive study of the 
immune mechanisms of vaccination with influenza vaccines against emerging variant 
viruses; (5) the development of the most reliable and standardized assays to measure 
post-vaccination immune response.
Currently, the FluMist LAIV, which was withdrawn from use in the USA and Europe in 2015 
due to reduced LAIV effectiveness against A/H1N1pdm09, was returned to the practice by 
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the CDC’s Advisory Committee on Immunization Practices (ACIP) (http://www.cidrap.umn.
edu/news-perspective/2018/02/cdc-vaccine-panel-brings-back-flumist-2018-19-season). It was 
noted that after the replacement of A/H1N1pdm09 vaccine strain in the quadrivalent LAIV, 
an immune response was achieved similar to that of highly immunogenic seasonal A/H1N1 
viruses circulating before 2009. Therefore, at present, much attention is paid to influenza vac-
cine strategies that target more broadly reactive antibodies which also apply to potentially 
pandemic vaccine strains.
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AGID agar gel immunodiffusion
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EID50 fifty percent egg infectious dose
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LAIV live attenuated influenza vaccine
MDCK Madin-Darby canine kidney
MDV master donor virus
MN microneutralization
p.i. post infection
WHO World Health Organization
NI neuraminidase-inhibiting
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